ABUS Earnings & Financial Statements
Arbutus Biopharma Corporation
$4.19
+$0.08(+1.95%)
46
Overall
60
Value
18
Tech
60
Quality
Market Cap
$642.23M
Volume
2.43M
52W Range
$3.50 - $5.45
Target Price
$5.50
ABUS earnings and financial statements: Arbutus Biopharma Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
ABUS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M |
| Operating income | -$38.16M | -$76.32M | -$78.10M | -$65.46M | -$73.52M |
| EBITDA | -$33.00M | -$66.06M | -$71.45M | -$61.94M | -$71.64M |
| Net income | -$33.50M | -$69.92M | -$72.85M | -$69.46M | -$76.25M |
| EPS (diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $94.62M | $131.71M | $144.40M | $195.42M | $204.49M |
| Total liabilities | $18.04M | $34.34M | $38.38M | $58.57M | $35.05M |
| Shareholders’ equity | $76.58M | $97.37M | $106.02M | $136.85M | $169.44M |
| Cash and equivalents | $18.01M | $36.33M | $26.29M | $30.78M | $109.28M |
| Long-term debt | $199.0K | $806.0K | $1.34M | $1.81M | $2.23M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$39.64M | -$64.85M | -$85.94M | -$35.36M | -$69.36M |
| Capital expenditure | $364.0K | -$182.0K | -$1.01M | -$512.0K | -$809.0K |
| Free cash flow | -$39.64M | -$65.03M | -$85.94M | -$35.87M | -$70.17M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABUS | $4.19 | +1.9% | 2.43M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arbutus Biopharma Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW